~~<i id='D76474BDFE'><strike id='D76474BDFE'><tt id='D76474BDFE'><pre id='D76474BDFE'></pre></tt></strike></i>~~

Home / fashion / knowledge

knowledge

2025-10-01 00:20:42

knowledge

author：leisure time 2025-10-01 00:20:42 Page View：16846

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date
Next article： DIEP, the 'gold standard' of breast reconstruction, is under threat